- Home
- MUX vs UPB Comparison
MUX vs UPB Comparison
Compare MUX & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MUX
- UPB
- Stock Information
- Founded
- MUX 1979
- UPB 2021
- Country
- MUX Canada
- UPB United States
- Employees
- MUX N/A
- UPB N/A
- Industry
- MUX Precious Metals
- UPB
- Sector
- MUX Basic Materials
- UPB
- Exchange
- MUX Nasdaq
- UPB NYSE
- Market Cap
- MUX 524.8M
- UPB 521.3M
- IPO Year
- MUX N/A
- UPB 2024
- Fundamental
- Price
- MUX $11.42
- UPB $11.20
- Analyst Decision
- MUX Strong Buy
- UPB Strong Buy
- Analyst Count
- MUX 2
- UPB 4
- Target Price
- MUX $15.25
- UPB $56.50
- AVG Volume (30 Days)
- MUX 924.4K
- UPB 500.3K
- Earning Date
- MUX 08-06-2025
- UPB 08-14-2025
- Dividend Yield
- MUX N/A
- UPB N/A
- EPS Growth
- MUX N/A
- UPB N/A
- EPS
- MUX N/A
- UPB N/A
- Revenue
- MUX $168,945,000.00
- UPB $2,296,000.00
- Revenue This Year
- MUX N/A
- UPB N/A
- Revenue Next Year
- MUX $0.31
- UPB N/A
- P/E Ratio
- MUX N/A
- UPB N/A
- Revenue Growth
- MUX N/A
- UPB N/A
- 52 Week Low
- MUX $6.38
- UPB $5.14
- 52 Week High
- MUX $11.46
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- MUX 76.46
- UPB N/A
- Support Level
- MUX $9.25
- UPB N/A
- Resistance Level
- MUX $11.24
- UPB N/A
- Average True Range (ATR)
- MUX 0.43
- UPB 0.00
- MACD
- MUX 0.15
- UPB 0.00
- Stochastic Oscillator
- MUX 100.00
- UPB 0.00
About MUX McEwen Mining Inc.
McEwen Mining Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company primarily generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. More than half of the company's gold output comes from the El Gallo 1 mine, while the remaining gold production and the majority of silver production are sourced from the San Jose mine. Geographically, most production occurs in the United States.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.